Congress schedules xylazine but gives manufacturers a year to comply
S. 545 — Combating Illicit Xylazine Act · Filed by Catherine Cortez Masto (D-NV) · 35 cosponsors · Introduced Feb 12, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds xylazine (a veterinary sedative increasingly diverted to illicit drug markets) to Schedule III of the Controlled Substances Act, making unauthorized possession a federal crime. It permits veterinarians and pharmacies to dispense xylazine to animal owners and government animal-control programs without triggering user registration, and gives manufacturers and practitioners a grace period (1 year for labeling, 60 days for registration) to comply with new security and recordkeeping rules before enforcement begins.
Why we flagged it
The bill's core function is to place xylazine under federal drug control and establish reporting requirements on its illicit prevalence. It is a public-health and law-enforcement measure, not a market-facing carve-out or subsidy.
What the text implies
- Grace periods (60 days for practitioner registration, 1 year for labeling/packaging) create a compliance window during which existing manufacturers and veterinary practitioners may continue operations under old rules, potentially delaying enforcement and allowing continued diversion.
- The bill exempts manufacturers from capital expenditure requirements for Schedule III security infrastructure, shifting compliance burden to smaller or newer entrants and potentially creating competitive advantage for incumbent manufacturers.
- No appropriations or funding mechanism is included for treatment, harm-reduction services, or detection/testing infrastructure, meaning the bill criminalizes xylazine use without funding public-health response.
- The Sentencing Commission directive to review penalties for xylazine offenses may result in mandatory minimums or enhanced sentences, potentially increasing incarceration for people with addiction rather than treatment access.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill addresses a genuine public-health crisis—xylazine is increasingly mixed into illicit opioid supplies, causing overdose deaths and complicating addiction treatment. However, the grace periods and exemptions for manufacturers and practitioners may delay enforcement and create a window for continued diversion, while the bill does not fund treatment, harm reduction, or detection infrastructure to help citizens already exposed.
Who stands to gain
- existing xylazine manufacturers (exempted from capital expenditure requirements)
- veterinary pharmaceutical suppliers
- law enforcement agencies (expanded enforcement authority)
Named in the bill
Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), Department of Health and Human Services (HHS), U.S. Sentencing Commission, Controlled Substances Act (CSA), Schedule III controlled substances
Where it stands
35 cosponsors: 19 Republicans, 15 Democrats, 1 Independents.
- Feb 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 12, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
- Mar 26, 2026 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
6 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $572,172 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 82% of bills with at least one filing.
Catherine Cortez Masto, the sponsor, reported $298,634 in PAC receipts in the 2026 cycle.
- American Veterinary Medical Association — $384,422 on 2 filings
- Peace Officers Research Association of California — $100,000 on 2 filings
- Sergeants Benevolent Association of New York City — $40,000 on 1 filing
- Drug Policy Alliance — $18,639 on 1 filing
- National Association of Criminal Defense Lawyers (nacdl) — $15,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (7,134 characters) on Jul 10, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress schedules xylazine but gives manufacturers a year to comply” QuorumCivic. https://share.quorumcivic.app/bill/119/s545 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.